Results 101 to 110 of about 18,708 (185)

Evaluating the effects of sacubitril/valsartan with ST-elevated myocardial infarction: a systematic review and meta-analysis. [PDF]

Ann Med Surg (Lond)
Kumar A, Kumar R, Kumari S, Muskan, Kashish, Kumar A, Kumari K, Kumari R, Hussain F, Simran, Jawad S.   +10 more
europepmc   +1 more source

Sacubitril valsartan combined with bisoprolol reduces doxorubicin-induced cardiotoxicity in rats by attenuating oxidative stress. [PDF]

Exp Biol Med (Maywood)
Liu P, Yang H, Li R, Huang H, Xu M.
europepmc   +1 more source

Global trend and predictors of non-labelled sacubitril-valsartan dosing: results from IKNOW-HF survey. [PDF]

ESC Heart Fail
Yaseen IF, Farhan HA, Gnanaraj JP, Fukaya H, Prameswari HS, Saldarriaga C, Kemaloğlu Öz T, Elhout SA, Díez-Villanueva P, Costanzo MR, Toma M, Elsheikh Ibrahim NOE, Dakhil ZA, Mewton N, Mullens W, IKNOW-HF investigators Group .   +15 more
europepmc   +1 more source

Heterogeneous benefit of early sacubitril/valsartan initiation after PCI in elderly patients with left ventricular dysfunction: myocardial recovery and mid-term cardiovascular outcomes. [PDF]

Front Cardiovasc Med
Li J, Tang C.
europepmc   +1 more source

Sacubitril/valsartan for the prevention of cancer therapy-related cardiac dysfunction: a systematic review and meta-analysis. [PDF]

Cardiooncology
Wu YJ, Lin HJ, Hung YH, Liao CW, Lin YH, Hung CS.   +5 more
europepmc   +1 more source

Repurposing the angiotensin II receptor blocker valsartan to inhibit penicillin-binding protein 3 and its mutants in <i>Haemophilus influenzae</i>: a comprehensive <i>in silico</i> approach. [PDF]

Front Bioinform
Kacha S, Arun J, Nargund N, Joshi T, Mathpal S, Ramaiah S, Anbarasu A.   +6 more
europepmc   +1 more source

Defective efferocytosis links autonomic dysfunction and atrial fibrillation: multi-omics integration and <i>in vivo</i> validation. [PDF]

Front Immunol
Zhang X, Du Y, Shi S, Liu Y, Ye Z, Chai R, Feng M, Li J, Zhang L, Song Q, Du B, Hu Y.   +11 more
europepmc   +1 more source

Bibliometric analysis of sacubitril/valsartan in the management of chronic kidney disease (2013-2025). [PDF]

Ren Fail
Liu P, He X, Luo X, Xie S, Li Y, Su B.
europepmc   +1 more source

Efficacy of Valsartan-HCTZ in hypertension: a cohort study exploring age as a key determinant. [PDF]

BMC Cardiovasc Disord
Rauf A, Shah Y, Ullah Z, Inayat F, Babaresh WM, Begum A, Ahmad S.   +6 more
europepmc   +1 more source

You evaluation of the PARACHUTE-HF trial: role of sacubitril/valsartan compared to enalapril on outcomes in patients with heart failure from Chagas' disease. [PDF]

Heart Fail Rev
Abramov D, Minhas AMK, Alexy T, Guimaraes PO, Lainscak M, Myhre PL.   +5 more
europepmc   +1 more source